Labcorp Holdings Inc. $LH Shares Bought by Dakota Wealth Management

Dakota Wealth Management lifted its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 98.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,303 shares of the medical research company’s stock after buying an additional 5,116 shares during the quarter. Dakota Wealth Management’s holdings in Labcorp were worth $2,958,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC acquired a new position in Labcorp in the 4th quarter valued at $991,000. Integrated Wealth Concepts LLC grew its position in shares of Labcorp by 7.9% in the first quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 177 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Labcorp by 52.2% in the first quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock valued at $82,353,000 after purchasing an additional 121,304 shares during the period. Asset Management One Co. Ltd. increased its stake in Labcorp by 3.4% in the second quarter. Asset Management One Co. Ltd. now owns 35,393 shares of the medical research company’s stock valued at $9,291,000 after purchasing an additional 1,161 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in Labcorp by 11.7% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 210,102 shares of the medical research company’s stock worth $55,154,000 after buying an additional 22,018 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the company. UBS Group lowered their price target on Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. JPMorgan Chase & Co. upped their price target on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Piper Sandler increased their price target on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Finally, Robert W. Baird upped their price objective on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Labcorp currently has an average rating of “Moderate Buy” and an average price target of $304.42.

Labcorp Trading Up 0.8%

Shares of LH opened at $287.56 on Wednesday. Labcorp Holdings Inc. has a one year low of $209.38 and a one year high of $293.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The company has a market capitalization of $23.84 billion, a P/E ratio of 27.49, a P/E/G ratio of 1.95 and a beta of 1.03. The stock has a 50-day moving average price of $266.52 and a 200 day moving average price of $269.64.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. During the same period in the previous year, the company earned $3.45 earnings per share. Labcorp’s quarterly revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Sell-side analysts forecast that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is currently 27.53%.

Insider Buying and Selling

In related news, CEO Adam H. Schechter sold 5,273 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total value of $1,499,535.74. Following the sale, the chief executive officer owned 87,343 shares of the company’s stock, valued at approximately $24,838,602.34. This trade represents a 5.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the company’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares of the company’s stock, valued at approximately $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.84% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.